Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069673 · ClinicalTrials.gov registry record
Abbott Cephea Mitral Valve Disease Registry
A clinical trial of Mitral Regurgitation and Mitral Valve Disease, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 19
- Study locations
NCT07069673 is a study of Mitral Regurgitation and Mitral Valve Disease that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 1,000 participants, roughly in line with the 986-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target. The trial reports 19 study locations across 14 states.
The verdict
NCT07069673, a study of Mitral Regurgitation and Mitral Valve Disease, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 19
- Study locations
Study Summary
The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of correcting symptomatic mitral valve disease on clinical outcomes in patients that could be candidates for Transcatheter Mitral Valve Replacement and may also inform future regulatory or reimbursement submission strategies for the Cephea Mitral Valve System.
Conditions Studied
Study Locations (19)
Tennessee
- TriStar Centennial Medical Center - Nashville
- Ascension Saint Thomas - Nashville
- Vanderbilt Heart & Vascular Institute - Nashville
Georgia
- Piedmont Heart Institute - Atlanta
- Emory University Hospital - Atlanta
New York
- St. Francis Hospital - Roslyn
- Montefiore Medical Center - Moses Campus - The Bronx
Texas
- Houston Methodist - Houston
- UTHealth Memorial Hermann - Houston
Arizona
- Phoenix Cardiovascular Research Group - Phoenix
California
- Los Robles Regional Medical Center - Thousand Oaks
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- Ascension St. Vincent - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07069673
The ClinicalTrials.gov registry entry for NCT07069673 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 986-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 0 interventions.
NCT07069673 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Tennessee, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT07069673 about?
NCT07069673 is a clinical study titled "Abbott Cephea Mitral Valve Disease Registry". The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of cor...
What is the current status of trial NCT07069673?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-08-13. Estimated completion is 2028-12.
What conditions does trial NCT07069673 study?
This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Disease, Mitral Stenosis, Mitral Annulus Calcification, Mitral Valve (MV) Regurgitation.
Who is sponsoring clinical trial NCT07069673?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069673 being conducted?
This trial has 19 study locations across Arizona, California, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
RECRUITING · NA
-
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
RECRUITING · NA
-
EFS of the CardioMech MVRS
RECRUITING · NA
-
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
RECRUITING
-
Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease
RECRUITING
-
In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.